Literature DB >> 4322068

An assessment of massive-dose chemotherapy of malignant disease.

D E Bergsagel.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1971        PMID: 4322068      PMCID: PMC1930832     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN: 0008-4409            Impact factor:   8.262


× No keyword cloud information.
  21 in total

1.  The effect of chemotherapy on acute leukemia in the human.

Authors:  E J FREIREICH; E A GEHAN; D SULMAN; D R BOGGS; E FREI
Journal:  J Chronic Dis       Date:  1961-12

2.  The clinical excursion into 5-fluo-rouracil.

Authors:  M A SCHNEIDERMAN
Journal:  Cancer Chemother Rep       Date:  1962-02

3.  A direct measurement of the radiation sensitivity of normal mouse bone marrow cells.

Authors:  J E TILL; E A McCULLOCH
Journal:  Radiat Res       Date:  1961-02       Impact factor: 2.841

4.  NIH clinical staff conference. Burkitt's tumor.

Authors:  P P Carbone; C W Berard; J M Bennett; J L Ziegler; M H Cohen; P Gerber
Journal:  Ann Intern Med       Date:  1969-04       Impact factor: 25.391

5.  Single versus multiple dose dactinomycin therapy of Wilms's tumor. A controlled co-operative study conducted by the Children's Cancer Study Group A (formerly Acute Leukemia Co-operative Chemotherapy Group A).

Authors:  J A Wolff; W A Newton; W Krivit; G J D'Angio
Journal:  N Engl J Med       Date:  1968-08-08       Impact factor: 91.245

6.  Effect of cyclophosphamide on advanced lung cancer and the hematological toxicity of large, intermittent intravenous doses.

Authors:  D E Bergsagel; G L Robertson; R Hasselback
Journal:  Can Med Assoc J       Date:  1968-03-16       Impact factor: 8.262

7.  Hematological recovery in the mouse following single doses of gamma radiation and cyclophosphamide.

Authors:  F A Valeriote; D C Collins; W R Bruce
Journal:  Radiat Res       Date:  1968-03       Impact factor: 2.841

8.  Effects of vinblastine on the proliferative capacity of L cells and their progress through the division cycle.

Authors:  N Bruchovsky; A A Owen; A J Becker; J E Till
Journal:  Cancer Res       Date:  1965-09       Impact factor: 12.701

9.  Who should treat acute leukemia?

Authors:  J F Holland
Journal:  JAMA       Date:  1969-09-08       Impact factor: 56.272

10.  Survival of Burkitt's lymphoma patients in Mulago Hospital, Uganda.

Authors:  R H Morrow; M C Pike; A Kisuule
Journal:  Br Med J       Date:  1967-11-11
View more
  7 in total

1.  20-hour combination chemotherapy in advanced breast cancer.

Authors:  J H Goldie; L A Price
Journal:  Br Med J       Date:  1977-10-22

2.  Neoplastic meningitis resulting from hematological malignancies: pharmacokinetic considerations and maximizing outcome.

Authors:  Jai Grewal; Marlon Saria; Harpreet K Grewal; Santosh Kesari
Journal:  Clin Investig (Lond)       Date:  2011-10

3.  Effects of cytotoxic immunosuppressants on tuberculin-sensitive lymphocytes in guinea pigs.

Authors:  A Winkelstein
Journal:  J Clin Invest       Date:  1975-12       Impact factor: 14.808

4.  Results of a phase 1 study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children and young adults with brain cancer.

Authors:  Denise A Caruso; Lisa M Orme; Alana M Neale; Fiona J Radcliff; Gerlinda M Amor; Wirginia Maixner; Peter Downie; Timothy E Hassall; Mimi L K Tang; David M Ashley
Journal:  Neuro Oncol       Date:  2004-07       Impact factor: 12.300

5.  Differential effects of immunosuppressants on lymphocyte function.

Authors:  A Winkelstein
Journal:  J Clin Invest       Date:  1973-09       Impact factor: 14.808

6.  5-year follow-up of cytotoxic chemotherapy as an adjuvant to surgery in carcinoma of the bronchus.

Authors:  H Stott; R J Stephens; W Fox; D C Roy
Journal:  Br J Cancer       Date:  1976-08       Impact factor: 7.640

7.  Fifteen-year follow-up of all patients in a study of post-operative chemotherapy for bronchial carcinoma.

Authors:  D J Girling; H Stott; R J Stephens; W Fox
Journal:  Br J Cancer       Date:  1985-12       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.